Published 2023 | Version v1
Journal article

Biomarkers in osteoarthritis: current status and outlook --- the FNIH Biomarkers Consortium PROGRESS OA study

  • 1. Sydney Musculoskeletal Health, Kolling Institute, Faculty of Medicine, University of Sydney, Australia and Rheumatology Department, Royal North Shore Hospital, 2065, St Leonards, NSW (Australia)
  • 2. Brigham and Women's Hospital, Harvard Medical School, Boston, MA (United States)
  • 3. Foundation for the National Institutes of Health, Bethesda, North, MD (United States)
  • 4. Duke Molecular Physiology Institute, and Department of Medicine, Duke University, Durham, NC (United States)

Description

Currently, no disease-modifying therapies are approved for osteoarthritis (OA) use. One obstacle to trial success in this field has been our existing endpoints' limited validity and responsiveness. To overcome this impasse, the Foundation for the NIH OA Biomarkers Consortium is focused on investigating biomarkers for a prognostic context of use for subsequent qualification through regulatory agencies. This narrative review describes this activity and the work underway, focusing on the PROGRESS OA study.

Availability note (English)

Available from: http://dx.doi.org/10.1007/s00256-023-04284-w

Additional details

Identifiers

Publishing Information

Journal Title
Skeletal Radiology
Journal Volume
52
Journal Issue
11
Journal Page Range
p. 2323-2339
ISSN
0364-2348
CODEN
SKRADI